Novel therapy approach in primary stroke prevention: simultaneous inhibition of endothelin converting enzyme and neutral endopeptidase in spontaneously hypertensive, stroke-prone rats improves survival

References

• Doyle KP, Simon RP, Stenzel-Poore MP. Mechanisms of ischemic brain damage. Neuropharmacology 2008; 55: 310–8.
   PubMed Web of Science ®Google Scholar
• Okamoto K, Yamori Y, Nagaoka A. Establishment of the stroke-prone spontaneously hypertensive Rats (SHR). Circ Res 1974;34/35: 143–53.
   Web of Science ®Google Scholar
• Dimagl U, Iadecola C, Moskowitz MA. Pathobiology of ischaemic stroke: an integrated view. Trends Neurosci 1999; 22: 391–7.
   PubMed Web of Science ®Google Scholar
• Davenport AP, Battistini B. Classification of endothelin receptors and antagonists in clinical development. Clin Sci (Lond) 2002;103(Suppl 48):1S-35.
   Google Scholar
• Estrada V, Tellez MJ, Moya J, Fernández-Durango R, Egido J, Fernández Cruz AF. High plasma levels of endothelin-1 and atrial natriuretic peptide in patients with acute ischemic stroke. Am J Hypertens 1994; 7: 1085–9.
   PubMed Web of Science ®Google Scholar
• Barone FC, White RF, Elliott JD, Feuerstein GZ, Ohlstein EH. The endothelin receptor antagonist SB 217242 reduces cerebral focal ischemic brain injury. J Cardiovasc Pharmacol 1995;26(Suppl 3):5404–7.
   Google Scholar
• Lehmberg J, Putz C, Furst M, Beck J, Baethmann A, Uhl E. Impact of the endothelin-A receptor antagonist BQ 610 on microcirculation in global cerebral ischemia and reperfusion. Brain Res 2003; 961: 277–86.
   PubMed Web of Science ®Google Scholar
• Rubattu S, Sciarretta S, Valenti V, Stanzione R, Volpe M. Natriuretic peptides: an update on bioactivity, potential therapeutic use, and implication in cardiovascular diseases. Am J Hypertens 2008; 21: 733–41.
   PubMed Web of Science ®Google Scholar
• Campbell DJ. Vasopeptidase inhibition: a double-edged sword? Hypertension 2003; 41: 383–9.
   PubMed Web of Science ®Google Scholar
• Akdemir G, Luer MS, Dujovny M, Misra M. Intraventricular atrial natriuretic peptide for acute intracranial hypertension. Neurol Res 1997; 19: 515–20.
   PubMed Web of Science ®Google Scholar
• Ogihara T, Rakugi H, Masuo K, Yu H, Nagano M, Mikami H. Antihypertensive effects of the neutral endopeptidase inhibitor SCH 42495 in essential hypertension. Am J Hypertens 1994; 7: 943–7.
   PubMed Web of Science ®Google Scholar
• Rademaker MT, Charles CJ, Espiner EA, Nicholls MG, Richards AM, Kosoglou T. Neutral endopeptidase inhibition: augmented atrial and brain natriuretic peptide, haemodynamic and natriuretic responses in ovine heart failure. Clin Sci (Lond) 1996; 91: 283–91.
   PubMed Web of Science ®Google Scholar
• Simonson MS. Endothelins: multifunctional renal peptides. Physiol Rev 1993; 73: 375–411.
   PubMed Web of Science ®Google Scholar
• Dickstein K, De Voogd HJ, Miric MP, Willenbrock R, Mitrovic V, Pacher R, et al. Effect of single doses of SLV306, an inhibitor of both neutral endopeptidase and endothelin-converting enzyme, on pulmonary pressures in congestive heart failure. Am J Cardiol 2004; 94: 237–9.
   PubMed Web of Science ®Google Scholar
• Thone-Reinke C, Simon K, Richter CM, Godes M, Neumayer HH, Thormählen D, et al. Inhibition of both neutral endopeptidase and endothelin-converting enzyme by 5LV306 reduces proteinuria and urinary albumin excretion in diabetic rats. J Cardiovasc Pharmacol 2004;44(Suppl 1):576–9.
   Google Scholar
• Thone-Reineke C, Olivier J, Godes M, Zart R, George I, Bauer C, et al. Effects of angiotensin-converting enzyme inhibition and calcium channel blockade on cardiac apoptosis in rats with 2K1C (two-kidney/one-clip) renovascular hypertension. Clin Sci (Lond) 2003; 104: 79–85.
   PubMed Web of Science ®Google Scholar
• Garcia JH, Wagner S, Liu KF, Hu XJ. Neurological deficit and extent of neuronal necrosis attributable to middle cerebral artery occlusion in rats. Statistical validation. Stroke 1995; 26: 627–34.
   PubMed Web of Science ®Google Scholar
• Xu J, Scholz A, Rosch N, Blume A, Unger T, Kreutz R, et al. Low-dose lithium combined with captopril prevents stroke and improves survival in salt-loaded, stroke-prone spontaneously hypertensive rats. J Hypertens 2005; 23: 2277–85.
   PubMed Web of Science ®Google Scholar
• Blezer EL, Nicolay K, Goldschmeding R, Jansen GH, Koomans HA, Rabelink TJ, et al. Early-onset but not late-onset endothelin-A-receptor blockade can modulate hyperten-sion, cerebral edema, and proteinuria in stroke-prone hyper-tensive rats. Hypertension 1999; 33: 137–44.
   PubMed Web of Science ®Google Scholar
• Touyz RM, Turgeon A, Schiffrin EL. Endothelin-A-receptor blockade improves renal function and doubles the lifespan of stroke-prone spontaneously hypertensive rats. J Cardiovasc Pharmacol 2000; 36: 5300–4.
   Google Scholar
• Gries J, Kretzschmar R, Neumann BW. Development of hypertension and life span in stroke-prone spontaneously hypertensive rats during oral long-term treatment with various antihypertensive drugs. J Cardiovasc Pharmacol 1989;13(Suppl 4):579–82.
   Google Scholar
• Mies G, Hermann D, Ganten U, Hossmann KA. Hemodynamics and metabolism in stroke-prone spontaneously hypertensive rats before manifestation of brain infarcts. J Cereb Blood Flow Metab 1999; 19: 1238–46.
   PubMed Web of Science ®Google Scholar
• Tagami M, Kubota A, Nara Y, Yamori Y. Detailed disease processes of cerebral pericytes and astrocytes in stroke-prone SHR. Clin Exp Hypertens A 1991; 13: 1069–75.
   PubMed Web of Science ®Google Scholar
• Volpe M, Iaccarino G, Vecchione C, Rizzoni D, Russo R, Rubattu S, et al. Association and cosegregation of stroke with impaired endothelium-dependent vasorelaxation in stroke prone, spontaneously hypertensive rats. J Clin Invest 1996; 98: 256–61.
   PubMed Web of Science ®Google Scholar
• Barone FC, Ohlstein EH, Hunter AJ, Campbell CA, Hadingham SH, Parsons AA, et al. Selective antagonism of endothelin-A-receptors improves outcome in both head trauma and focal stroke in rat. J Cardiovasc Pharmacol 2000; 36: 5357–61.
   Web of Science ®Google Scholar
• Hocher B, Thone-Reineke C, Rohmeiss P, Schmager F, Slowinski T, Burst V, et al. Endothelin-1 transgenic mice develop glomerulosclerosis, interstitial fibrosis, and renal cysts but not hypertension. J Clin Invest 1997; 99: 1380–9.
   PubMed Web of Science ®Google Scholar
• Sironi L, Guerrini U, Tremoli E, Miller I, Gelosa P, Lascialfari A, et al. Analysis of pathological events at the onset of brain damage in stroke-prone rats: a proteomics and magnetic resonance imaging approach. J Neurosci Res 2004; 78: 115–22.
   PubMed Web of Science ®Google Scholar
• Lee JM, Zhai G, Liu Q, Gonzales ER, Yin K, Yan P, et al. Vascular permeability precedes spontaneous intracerebral hemorrhage in stroke-prone spontaneously hypertensive rats. Stroke 2007; 38: 3289–91.
   PubMed Web of Science ®Google Scholar
• Matsuo Y, Mihara S, Ninomiya M, Fujimoto M. Protective effect of endothelin type A receptor antagonist on brain edema and injury after transient middle cerebral artery occlusion in rats. Stroke 2001; 32: 2143–8.
   PubMed Web of Science ®Google Scholar
• Narushima I, Kita T, Kubo K, Yonetani Y, Momochi C, Yoshikawa I, et al. Highly enhanced permeability of blood-brain barrier induced by repeated administration of endothelin-1 in dogs and rats. Pharmacol Toxicol 2003; 92: 21–6.
   PubMedGoogle Scholar
• ClinicalTrials.gov. To determine the effects of avosentan on doubling of serum creatinine, end stage renal disease and death in diabetic nephropathy. Basel: Speedel Pharma Ltd; 2008.
   Google Scholar
• Ovbiagele B. Impairment in glomerular filtration rate or glomerular filtration barrier and occurrence of stroke. Arch Neurol 2008; 65: 934–8.
   PubMedGoogle Scholar
• Dhaun N, Goddard J, Kohan DE, Pollock DM, Schiffrin EL, Webb DJ. Role of endothelin-1 in clinical hypertension: 20 years on. Hypertension 2008; 52: 452–9.
   PubMed Web of Science ®Google Scholar
• Ibsen H, Olsen MH, Wachtell K, Borch-Johnsen K, Lindholm LH, Mogensen CE, et al. Reduction in albuminuria translates to reduction in cardiovascular events in hypertensive patients: losartan intervention for endpoint reduction in hypertension study. Hypertension 2005; 45: 198–202.
   PubMed Web of Science ®Google Scholar
• Hillege HL, Fidler V, Diercks GF, van Gilst WH, de Zeeuw D, van Veldhuisen DJ, et al. Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population. Circulation 2002; 106: 1777–82.
   PubMed Web of Science ®Google Scholar
• O'Connell JE, Jardine AG, Davidson G, Connell JM. Candoxatril, an orally active neutral endopeptidase inhibitor, raises plasma atrial natriuretic factor and is natriuretic in essential hypertension. J Hypertens 1992; 10: 271–7.
   PubMed Web of Science ®Google Scholar